Baldwin Wealth Partners LLC MA Has $3.50 Million Stake in Nuvectis Pharma, Inc. (NASDAQ:NVCT)

Baldwin Wealth Partners LLC MA increased its holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 0.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 358,461 shares of the company’s stock after buying an additional 2,500 shares during the period. Baldwin Wealth Partners LLC MA owned 1.53% of Nuvectis Pharma worth $3,502,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Marshall Wace LLP boosted its holdings in shares of Nuvectis Pharma by 191.0% during the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company’s stock valued at $674,000 after acquiring an additional 81,757 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in Nuvectis Pharma in the 4th quarter valued at approximately $135,000. Squarepoint Ops LLC bought a new stake in shares of Nuvectis Pharma during the 4th quarter valued at about $103,000. Northern Trust Corp grew its stake in Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company’s stock worth $139,000 after purchasing an additional 10,472 shares during the period. Finally, Blue Zone Wealth Advisors LLC acquired a new position in Nuvectis Pharma in the first quarter valued at approximately $102,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVCT has been the topic of several research analyst reports. Maxim Group assumed coverage on shares of Nuvectis Pharma in a research note on Wednesday, April 2nd. They set a “buy” rating and a $17.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th. Finally, Laidlaw started coverage on Nuvectis Pharma in a research note on Monday, March 17th. They issued a “buy” rating and a $19.00 price objective for the company.

Insiders Place Their Bets

In other news, major shareholder Marlio Charles Mosseri purchased 21,167 shares of Nuvectis Pharma stock in a transaction dated Monday, May 12th. The stock was purchased at an average cost of $8.11 per share, for a total transaction of $171,664.37. Following the transaction, the insider now directly owns 2,942,761 shares of the company’s stock, valued at approximately $23,865,791.71. This trade represents a 0.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders purchased a total of 36,261 shares of company stock worth $301,481 in the last quarter. 30.52% of the stock is owned by company insiders.

Nuvectis Pharma Stock Down 1.3%

Shares of NASDAQ:NVCT opened at $8.85 on Monday. The firm has a market capitalization of $184.91 million, a PE ratio of -7.63 and a beta of -0.16. The company has a 50-day moving average price of $9.30 and a two-hundred day moving average price of $7.47. Nuvectis Pharma, Inc. has a twelve month low of $4.44 and a twelve month high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. Analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.